查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1672784

肺炎鏈球菌疫苗市場按疫苗類型、目標族群、接種途徑、通路和地區分類

Pneumococcal Vaccines Market, By Vaccine Type, By Target Population, By Route of Administration, By Distribution Channel, By Geography
出版日期: | 出版商: Coherent Market Insights | 英文 150 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2025 年全球肺炎鏈球菌疫苗市場規模估計為 93.8 億美元，預計到 2032 年將達到 132.9 億美元，2025 年至 2032 年的複合年成長率為 5.1%。

報告範圍 報告詳細資訊
基準年 2024 2025 年市場規模 93.8億美元
效能資料 從 2020 年到 2024 年 預測期 2025 至 2032 年
預測期：2025-2032年複合年成長率： 5.10% 2032 年價值預測 132.9億美元
數字。 2025 年肺炎鏈球菌疫苗市場佔有率（按地區分類）
肺炎鏈球菌疫苗市場-IMG1

全球肺炎鏈球菌疫苗市場的成長受到世界範圍內肺炎球菌疾病發病率上升以及世界各國政府實施的疫苗接種計劃增加等因素的推動。此外，人們對肺炎球菌疫苗接種認知的不斷提高也推動了市場的成長。然而，開發和生產肺炎球菌疫苗的高成本可能會阻礙市場成長。正在進行的開發經濟實惠且有效疫苗的研究工作可能會在不久的將來提供新的機會。

市場動態：

全球肺炎球菌疫苗市場的成長主要受到肺炎、腦膜炎和肺炎球菌肺炎引起的其他嚴重感染疾病在全球日益流行的推動。根據世界衛生組織（WHO）的數據，肺炎是五歲以下兒童五大死因之一。此外，增加政府資金和透過國家免疫計劃推廣疫苗接種計劃的舉措可能會推動市場成長。然而，肺炎球菌疫苗的高研發和製造成本可能會阻礙市場擴張。正在進行的評估新型多效價肺炎鏈球菌製劑的安全性和有效性的臨床試驗可能會推動市場成長。新興經濟體已經發達了醫療保健基礎設施，這對市場進入者來說是一個巨大的機會。

本研究的主要特點

本報告對全球肺炎球菌疫苗市場進行了詳細分析，並給出了預測期（2025-2032 年）的市場規模（十億美元）和年複合成長率（CAGR%），假設 2024 年為基準年。

它還強調了各個領域的潛在商機並解釋了該市場的有吸引力的投資提案矩陣。

它還提供了關於市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景和主要企業採用的競爭策略的主要考察。

全球肺炎球菌疫苗市場的主要企業是根據公司亮點、產品系列、關鍵亮點、績效和策略等參數進行分析的。

主要公司包括輝瑞、默克、葛蘭素史克、賽諾菲等。

本報告提供的見解將使負責人和企業經營團隊能夠就未來產品發布、新興趨勢、市場擴張和行銷策略做出明智的決策。

全球肺炎球菌疫苗市場報告迎合了該行業的各個相關人員，例如投資者、供應商、產品製造商、經銷商、新進入者和金融分析師。

目錄

第1章 調查目的與前提條件

  • 研究目標
  • 先決條件
  • 簡稱

第2章 市場展望

  • 報告描述
    • 市場定義和範圍
  • 執行摘要

第3章市場動態、法規與趨勢分析

  • 市場動態
  • 影響分析
  • 主要亮點
  • 監管情景
  • 產品發布/核准
  • PEST分析
  • PORTER 分析
  • 併購情景

4. 2020 年至 2032 年全球肺炎鏈球菌疫苗市場（以疫苗類型分類）（十億美元）

  • 肺炎鏈球菌結合疫苗（PCV）
  • 肺炎鏈球菌多醣體疫苗（PPV）

5. 2020 年至 2032 年全球肺炎鏈球菌疫苗市場（以目標族群分類）（十億美元）

  • 成人（65 歲以上）
  • 兒童（5歲以下）
  • 高危險群成人（18-64 歲）

6. 2020 年至 2032 年全球肺炎鏈球菌疫苗市場（依給藥途徑分類）（十億美元）

  • 肌肉注射
  • 皮下

7. 2020-2032 年全球肺炎鏈球菌疫苗市場按分銷管道分類（十億美元）

  • 醫院藥房
  • 零售藥局
  • 網路藥局

8. 2020 年至 2032 年全球肺炎鏈球菌疫苗市場（按地區分類）（十億美元）

  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 亞太地區
  • 中東
  • 非洲

第9章 競爭格局

  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc（GSK）
  • Sanofi
  • CSL Limited
  • Serum Institute of India Pvt. Ltd.
  • Vaxcyte, Inc.
  • Astellas Pharma Inc.
  • Panacea Biotec Ltd.
  • Walvax Biotechnology Co., Ltd.
  • Beijing Minhai Biotechnology Co., Ltd.
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biovac
  • Bharat Biotech
  • Inovio Pharmaceuticals, Inc.
  • Hilleman Laboratories Pvt. Ltd

第 10 章分析師建議

第 11 章 參考文獻與調查方法

  • 參考
  • 調查方法
  • 關於出版商
簡介目錄
Product Code: CMI2295

Global Pneumococcal Vaccines Market is estimated to be valued at USD 9.38 Bn in 2025 and is expected to reach USD 13.29 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.1% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 9.38 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.10% 2032 Value Projection: USD 13.29 Bn
Figure. Pneumococcal Vaccines Market Share (%), By Region 2025
Pneumococcal Vaccines Market - IMG1

Global pneumococcal vaccines market growth is driven by factors such as rising incidence of pneumococcal diseases worldwide and growing immunization programs by various governments. Moreover, increasing awareness among people regarding pneumococcal vaccination can also drive the market growth. However, high costs associated with pneumococcal vaccines development and production can hamper the market growth. Ongoing research activities for developing affordable and effective vaccines can offer new opportunities in the near future.

Market Dynamics:

Global pneumococcal vaccines market growth is primarily driven by rising prevalence of pneumococcal pneumonia, meningitis, and other serious infections caused by Streptococcus pneumoniae bacteria worldwide. As per the World Health Organization (WHO), pneumonia is one of the top five causes of death in children under age of 5 years. Moreover, increasing government funding and initiatives to promote immunization programs through national immunization schedules can drive the market growth. However, high research, development and production costs of pneumococcal vaccines can hamper the market expansion. Ongoing clinical trials assessing the safety and efficacy of new multivalent pneumococcal formulations can drive the market growth. Emerging economies present significant opportunities for market players owing to improving healthcare infrastructures in these countries.

Key features of the study:

This report provides in-depth analysis of the global pneumococcal vaccines market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pneumococcal vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include Pfizer Inc., Merck & Co., GSK plc., and Sanofi

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

Global pneumococcal vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Detailed Segmentation-

  • By Vaccine Type
    • Pneumococcal Conjugate Vaccines (PCVs)
    • PCV13 (Prevnar 13/Prevenar 13)
    • PCV10 (Synflorix)
    • PCV7 (Prevnar/Prevenar)
    • Pneumococcal Polysaccharide Vaccines (PPVs)
    • PPSV23 (Pneumovax 23)
    • PPSV14 (Pneumo 14)
  • By Target Population
    • Adults (>= 65 years)
    • Children (< 5 years)
    • High-Risk Adults (18-64 years)
  • By Route of Administration
    • Intramuscular
    • Subcutaneous
  • By Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • By Region:
    • North America
    • Europe
    • Asia Pacific
    • Latin America
    • Middle East & Africa
  • Key Players Insights
    • Pfizer Inc.
    • Merck & Co., Inc.
    • GlaxoSmithKline plc (GSK)
    • Sanofi
    • CSL Limited
    • Serum Institute of India Pvt. Ltd.
    • Vaxcyte, Inc.
    • Astellas Pharma Inc.
    • Panacea Biotec Ltd.
    • Walvax Biotechnology Co., Ltd.
    • Beijing Minhai Biotechnology Co., Ltd.
    • Merck KGaA
    • Takeda Pharmaceutical Company Limited
    • AbbVie Inc.
    • Novartis AG
    • Johnson & Johnson
    • Biovac
    • Bharat Biotech
    • Inovio Pharmaceuticals, Inc.
    • Hilleman Laboratories Pvt. Ltd

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Pneumococcal Vaccines Market, By Vaccine Type
    • Global Pneumococcal Vaccines Market, By Target Population
    • Global Pneumococcal Vaccines Market, By Route of Administration
    • Global Pneumococcal Vaccines Market, By Distribution Channel
    • Global Pneumococcal Vaccines Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Impact Analysis
  • Key Highlights
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario

4. Global Pneumococcal Vaccines Market, By Vaccine Type, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Pneumococcal Conjugate Vaccines (PCVs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • PCV13 (Prevnar 13/Prevenar 13)
    • PCV10 (Synflorix)
    • PCV7 (Prevnar/Prevenar)
  • Pneumococcal Polysaccharide Vaccines (PPVs)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
    • PPSV23 (Pneumovax 23)
    • PPSV14 (Pneumo 14)

5. Global Pneumococcal Vaccines Market, By Target Population, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Adults (>= 65 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Children (< 5 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • High-Risk Adults (18-64 years)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Pneumococcal Vaccines Market, By Route of Administration, 2020-2032, (USD Bn)

  • Intramuscular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Pneumococcal Vaccines Market, By Distribution Channel, 2020-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2021 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Pneumococcal Vaccines Market, By Region, 2020 - 2032, (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2021- 2032, (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Vaccine Type, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Target Population, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Route of Administration, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
    • Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

9. Competitive Landscape

  • Pfizer Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck & Co., Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • GlaxoSmithKline plc (GSK)
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Sanofi
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • CSL Limited
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Serum Institute of India Pvt. Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Vaxcyte, Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Astellas Pharma Inc.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Panacea Biotec Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Walvax Biotechnology Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Beijing Minhai Biotechnology Co., Ltd.
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies
  • Merck KGaA
  • Takeda Pharmaceutical Company Limited
  • AbbVie Inc.
  • Novartis AG
  • Johnson & Johnson
  • Biovac
  • Bharat Biotech
  • Inovio Pharmaceuticals, Inc.
  • Hilleman Laboratories Pvt. Ltd

10. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

11. References and Research Methodology

  • References
  • Research Methodology
  • About us